Table 2.
Baseline serology status and post-baseline HBV DNA detectability by geographical region
| Baseline serology status/ HBV DNA detectability |
Japan | China | Taiwan | South Korea | North America | South America | European Union | Rest of world | Total |
| Total patients* | 371 | 50 | 92 | 84 | 601 | 655 | 669 | 359 | 2881 |
| Total receiving post-baseline DNA test, n (%) | 82 (22) | 20 (40) | 46 (50) | 36 (43) | 24 (4) | 18 (3) | 31 (5) | 33 (9) | 290 |
| HBsAb−/HBcAb−, n (%) | 303 (82) | 15 (30) | 26 (28) | 18 (21) | 496 (83) | 582 (89) | 526 (79) | 283 (79) | 2249 |
| Received post-baseline DNA test | 15 | 0 | 0 | 2 | 8 | 6 | 7 | 7 | 45 |
| Undetectable HBV DNA | 15 | 0 | 0 | 2 | 7 | 6 | 6 | 7 | 43 |
| HBV DNA <29 IU/mL | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 2 |
| HBV DNA ≥29 IU/mL | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HBsAb+/HBcAb−, n (%) | 14 (4) | 13 (26) | 19 (21) | 35 (42) | 87 (14) | 61 (9) | 91 (14) | 43 (12) | 363 |
| Received post-baseline DNA test | 14 | 0 | 2 | 5 | 4 | 2 | 2 | 1 | 30 |
| Undetectable HBV DNA | 12 | 0 | 2 | 5 | 4 | 2 | 2 | 1 | 28 |
| HBV DNA <29 IU/mL | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| HBV DNA ≥29 IU/mL | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| HBsAb+/HBcAb+, n (%) | 46 (12) | 21 (42) | 47 (51) | 31 (37) | 17 (3) | 11 (2) | 52 (8) | 30 (8) | 255 |
| Received post-baseline DNA test | 45 | 19 | 44 | 29 | 11 | 9 | 22 | 22 | 201 |
| Undetectable HBV DNA | 39 | 8 | 38 | 28 | 10 | 8 | 21 | 19 | 171 |
| HBV DNA <29 IU/mL | 4 | 11 | 3 | 0 | 1 | 0 | 1 | 3 | 23 |
| HBV DNA ≥29 IU/mL | 2 | 0 | 3 | 1 | 0 | 1 | 0 | 0 | 7 |
| HBsAb−/HBcAb+, n (%) | 8 (2) | 1 (2) | 0 (0) | 0 (0) | 1 (0) | 1 (0) | 0 (0) | 3 (1) | 14 |
| Received post-baseline DNA test | 8 | 1 | 0 | 0 | 1 | 1 | 0 | 3 | 14 |
| Undetectable HBV DNA | 7 | 1 | 0 | 0 | 1 | 1 | 0 | 2 | 12 |
| HBV DNA <29 IU/mL | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| HBV DNA ≥29 IU/mL | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
HBcAb, hepatitis B virus core antibody; HBsAb, hepatitis B virus surface antibody; HBV, hepatitis B virus.
*Total number of patients with baseline serology is n=2881 owing to missing data for nine patients (five patients from North America; three patients from South America; one patient from European Union).